Differences in changes in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides (expressed as mg/dL) between patients with hyperlipidaemia.

Slides:

Advertisements

Similar presentations

Exercise the Medicine of Choice Reducing Cardiovascular Risk Dr. Lynn Panton Florida State University College of Human Sciences Department of Nutrition,

Advertisements

Women and Cholesterol What You Need to Know. Age: 45 Women and Cholesterol: What You Need to Know HDL: 60 mg/dL and above LDL: Below 100 mg/dL GoodBad.

Lipoproteins/Particles

© 2003, Wellsource Inc. Effect of Ketogenic Diet on Lipid Levels (shown is LDL-C) In this group of 141 children followed for 6 months, a ketogenic diet.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Dyslipidemia and Diabetic Macular Edema

Supplemental Figure 1 A B C D E F

Copyright © 2011 American Medical Association. All rights reserved.

Nonproliferative DR (n=24)

LDL cholesterol in CKD—to treat or not to treat?

Robert Roberts, MD, FRCPC, MACC Canadian Journal of Cardiology

HbA1c 1245_0025final study-report-body. Table : 1 HbA1c (%) change from baseline MMRM results over time − FAS (OC−AD)

© The Author(s) Published by Science and Education Publishing.

Copyright © 2012 American Medical Association. All rights reserved.

Time frame : Baseline to post intervention

Classification of total cholesterol levels

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

What is the likely mechanism by which HDL-C reduces coronary heart disease?

TNT: Baseline and final LDL cholesterol levels

Behavior and Biology: The Basic Sciences for AHA Action

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Figure 7 Mendelian randomization of overlapping exposures

Association of low eosinophil and lymphocyte counts with different initial presentations of cardiovascular disease over the first 6 months ‘Low eosinophils’

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Martin W. Schoen, MD, MPH, Joanne Salas, MPH, Jeffrey F

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Rounding numbers The Journal of Thoracic and Cardiovascular Surgery

Effect of evolocumab on lipoprotein particles

Fellström BC, et al. N Engl J Med 2009;360:1455-7

How to Teach it?.

Joshua A. Bell et al. JACC 2018;72:

James H. O'Keefe, M.D., Carl J. Lavie, M.D., Ben D. McCallister, M.D.

II. assessment of dyslipidemias

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

OR (95% CI) for CHD associated with inflammatory markers before and after adjustment for established risk factors. OR (95% CI) for CHD associated with.

Primary and Secondary Prevention of Cardiovascular Disease

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Level of risk factor control in the overall sample and by gender

Influence of possible intermediary variables on PR interval mean difference (95% CI) between HIV-infected (ART-naïve or ART-exposed) children and healthy.

Khurram Nasir et al. JACC 2015;66:

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

LDL cholesterol in CKD—to treat or not to treat?

Comparison of clinical and functional parameters between the CMV+ and CMV− participants in the healthy elderly and elderly patients with T2DM. Comparison.

Baseline Characteristics of the Subjects*

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Volume 87, Issue 1, Pages (January 2015)

The test score you want to be high…

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

Characteristics of included studies

Receiver operating curves (ROC) of simple age and gender adjusted risk factor models for predicting 10-year risk of cardiovascular disease comparing the.

Lars E. Laugsand et al. BTS 2016;j.jacbts

Influence of possible intermediary variables on QTc interval mean difference (95% CI) between HIV-infected (ART-naïve or ART-exposed) children and healthy.

Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

The ACCORD Study Group. NEJM 2010; Epub March 14

Change in markers of glycometabolism and cardiovascular risk profile.

Amir A. Mahabadi et al. JIMG 2017;10:

Correlation of 75selenohomocholic acid taurate (SeHCAT) 7-day retention (%) with low-density lipoprotein (LDL) cholesterol (A) and triglycerides (TG) (B)

III. Treating dyslipidemias

Determinants of moderate Cardiovascular Health Index Score (CHIS) (achieving three or more risk factor targets). Determinants of moderate Cardiovascular.

in diabetic patients with mixed dyslipidemia

Individual lipid measures for high-carbohydrate (n=10) and low-carbohydrate (n=10) ultra-endurance athletes. Individual lipid measures for high-carbohydrate.

FIGURE 1 Results for primary meta-analysis of controlled trials for the effects of walnut-enriched compared with ... FIGURE 1 Results for primary meta-analysis.

International Journal of Cardiology

© The Author(s) Published by Science and Education Publishing.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Medication intensity (ALLP) changes between baseline and 6 months, by (not) being low-density lipoprotein-cholesterol (LDL-C) target at baseline for nurse-coordinated.

Presentation transcript:

Differences in changes in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides (expressed as mg/dL) between patients with hyperlipidaemia receiving a pharmacist’s intervention and patients in control groups in a meta-analysis of different s... Differences in changes in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides (expressed as mg/dL) between patients with hyperlipidaemia receiving a pharmacist’s intervention and patients in control groups in a meta-analysis of different studies. Data are shown as mean difference and 95% CI (redrawn from 18 with permission). HDL, high density lipoprotein; LDL, low density lipoprotein. Stefano Omboni, and Marina Caserini Open Heart 2018;5:e000687 ©2018 by British Cardiovascular Society